The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, has added SAB-185, a polyclonal antibody therapy, to the COVID-19 outpatient treatment study.
Clinical trials have begun on a new vaccine candidate that may protect against variants of the SARS-CoV-2 virus. Protein structures determined at the Advanced Photon Source helped to guide the development of this vaccine.
A Phase II clinical trial to assess mesenchymal adult stem cells as a disease-modifying therapy for Parkinson's disease has been launched at The University of Texas Health Science Center at Houston (UTHealth).
Moores Cancer Center at UC San Diego Health is among the few clinical trial sites in the U.S. for the Pancreatic Cancer Action Network’s (PanCAN) newly created Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
A large national clinical trial to evaluate the Pfizer-BioNTech COVID-19 vaccine for safety and efficacy in pregnant women is now open for enrollment at The University of Texas Health Science Center at Houston (UTHealth).
A clinical trial to assess the safety and efficacy of stem cell therapy for treatment-resistant bipolar depression launched recently at The University of Texas Health Science Center at Houston (UTHealth).
The University of Chicago Medicine is enrolling patients in LymphBridge™, a randomized clinical study to evaluate a novel surgical treatment for addressing breast cancer-related lymphedema.
Researchers with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine and Vertex Pharmaceuticals Incorporated have initiated clinical trials for VX-880, a novel investigational cell therapy with the potential to restore normal glucose control in people suffering from type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness. The University of Miami Health System was the first clinical site activated for this trial.
Reducing health disparities by examining the effectiveness of tools that encourage end-of-life conversations may improve the likelihood that underserved patients receive care that is consistent with their values and beliefs.
Researchers at Michigan Medicine are helping lead the first national study of how highly allergic people react to mRNA COVID-19 vaccines. The trial, co-led by a U-M immunologist, will cover over 3,000 participants receiving the Pfizer and Moderna vaccines at up to 35 academic allergy research centers across the United States.
February 18, 2021 – King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Chula Faculty of Medicine, and Chula Vaccine Research Center (Chula VRC) jointly held a press conference on “The latest development on ChulaCov19 vaccine and its readiness for clinical trial”. On the panel were H.E. Anutin Charnvirakul, Deputy Prime Minister and Public Health Minister; Dr. Nakorn Premsri, the Director of National Vaccine Institute (NVI); Prof.Dr. Suttipong Wacharasindhu, Director of King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and Dean of Chula Faculty of Medicine; and Dr.Kiat Ruxrungtham, Director of Chula Vaccine Research Center (Chula VRC). The event was moderated by Assoc. Prof. Dr. Jiruth Sriratanaban, Deputy Director of King Chulalongkorn Memorial Hospital.
New immunotherapy approach to treating cancer patients with COVID-19 aims to reduce risk of severe COVID-19 symptoms by reinvigorating patients' cellular immune responses
A new CoVPN study evaluating SARS-CoV-2 infection and transmission among college students vaccinated with the Moderna COVID-19 vaccine was announced today. The new trial will tell us whether a person can become infected after they’ve been vaccinated and if the vaccine will stop the virus from spreading person-to-person.
Henry Ford Health System is studying an investigational cell therapy known as CardiAMP. in a Phase III clinical trial for patients who have previously suffered myocardial infarction, also known as a heart attack, and subsequently developed heart failure, which is when the heart cannot pump enough blood and oxygen to support other organs in the body.
A comprehensive review of the current CRISPR clinical trials landscape, covering progress on blood disorders, cancers, eye disease, chronic infection, rare protein-folding disease, and future prospects.
University Hospitals in Cleveland to be a clinical research site of a trial evaluating investigational drug RHB-107, also know as Upamostat, for COVID-19 in patients who do not require hospitalization.
The Psychedelics and Health Research Initiative at UC San Diego has received a $1.3 million grant from the Steven & Alexandra Cohen Foundation to fund a clinical trial investigating the therapeutic potential of psilocybin in treating phantom limb pain.
The AIDS Clinical Trials Group has added rapid infusion, intramuscular injection, an inhalant, and an oral agent to its ACTIV-2 phase 2 and 3 evaluations of multiple investigational agents for treating early, symptomatic COVID-19 in a single trial for outpatient treatment.
The McMaster research team is partnering with research clinic Cardresearch and the Pontifical Catholic University of Minas Gerais in Brazil as well as the University of Stellenbosch in South Africa on an ongoing clinical trial established to answer multiple questions of drug effectiveness over time.
A new drug candidate has been discovered by the University of South Australia (UniSA) to treat the most lethal form of brain cancer – glioblastoma – which kills 95 per cent of patients within five years. Clinical trials will begin this year.
A single patient will help researchers learn if brain implants connected to a robotic brace can help stroke patients overcome abnormal movement and restore abilities.
Rheoscan (model: Rheoscan-And300, Rheoscan-D300) system is an in vitro diagnostic device that tests the erythrocyte deformability, aggregation, and critical shear stress used as a POC device.
Clinical trial finds that full-dose treatment with blood thinner reduces need for vital organ support in ICUs in moderately ill hospitalized COVID-19 patients.
The Center for Food Allergy & Asthma Research (CFAAR), at Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago, announced the launch of the Intervention to Reduce Early Peanut Allergy in Children (iREACH) study. iREACH is a five-year, randomized clinical trial, funded by the National Institutes of Health (NIH), aimed at assessing and improving pediatric clinician adherence to the 2017 prevention of peanut allergy guidelines developed by an expert panel sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
Today, the Pulmonary Fibrosis Foundation (PFF) announced enrollment of the first patient in PRECISIONS (Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection) clinical trial. This is the first clinical trial to apply the principles of precision medicine to the treatment of patients with idiopathic pulmonary fibrosis (IPF).
The AIDS Clinical Trials Group (ACTG) has added a new agent to the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. This phase 2 study, which is being led by the ACTG, will evaluate the combination of the two monoclonal antibodies BRII-196 and BRII-198 to treat early COVID-19.
Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network which has treated more COVID-19 patients than any other health system in the state, is now enrolling individuals in the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 COVID-19 vaccine trial.
FLCCC physicians: “Ivermectin will remain a potent anti-viral even against mutant strain.”
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.
The first patient has enrolled in a Phase II clinical trial evaluating a stem cell therapy for the potential early treatment of traumatic injuries and their subsequent complications at The University of Texas Health Science Center at Houston (UTHealth).
University of Miami Miller School of Medicine researchers have begun recruiting for a study looking at the impact of the COVID-19 vaccine on male fertility. The Miller School is the first institution studying the effects on sperm of men who receive the vaccine, according to the study’s principal investigator, Ranjith Ramasamy, M.D., associate professor and director of reproductive urology.
Amphivena Therapeutics, a clinical-stage oncology company focused on developing a platform of bivalent T-cell engagers that restore anti-cancer immunity in patients, today announced the first patient has been dosed in the Phase 1 dose expansion study evaluating AMV564, an investigational, first-in-class agent that depletes myeloid derived suppressor cells (MDSC) and activates T cells, in adult patients with selected solid tumor indications.
Researchers are investigating whether a human umbilical cord patch placed on the spina bifida defect could improve healing after minimally invasive fetoscopic surgery in a clinical trial at UTHealth.
A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics took a major step toward becoming a first-in-class treatment for Fragile X Syndrome, a leading genetic cause of autism.
The study will explore pacritinib as a treatment for cytokine storm in hospitalized patients with severe COVID-19. Pacritinib is a new type of oral kinase inhibitor—a drug that blocks enzymes that may cause cancer cells to grow. As a multi-kinase inhibitor, pacritinib has the potential to prevent an inflammatory response that frequently leads to respiratory failure in severe COVID-19. The study will evaluate pacritinib in hospitalized patients with severe COVID-19 with or without cancer. Patients discharged from the hospital will complete their study treatment on an outpatient basis. The PRE-VENT study is sponsored by CTI BioPharma.
Bernard Thurman was referred to a personalized cancer therapy trial at Moores Cancer Center at UC San Diego Health, a collaboration with the La Jolla Institute for Immunology, the trial employs a patient’s immune cells — specifically tumor infiltrating lymphocytes (TIL) — to destroy cancer cells.
UC Davis Health will launch a COVID-19 clinical trial with Novavax to test a new coronavirus vaccine. This vaccine has an important advantage: liquid state storage that allows for distribution using standard vaccine channels, unlike the Pfizer and Moderna vaccines that must be stored at subzero temperature.
Corporations do not vote in elections, but their impact on democratic societies is immense.
CEL-SCI Corporation announced today its LEAPS COV-19 peptides, delivered as a therapeutic treatment following SARS-CoV-2 virus challenge, achieved a 40% survival rate in transgenic mouse models as compared to 0% survival in the two control groups in studies conducted at the University of Georgia Center for Vaccines and Immunology.
Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.
Maryland-based Altimmune Inc., a clinical stage biopharmaceutical company, has submitted an Investigational New Drug, or IND, application to the United States Food and Drug Administration to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Researchers are assessing whether magnetic seizure therapy (MST) can help relieve treatment-resistant depression in bipolar patients in a clinical trial led by UTHealth.
Despite advances in cancer treatment, disparities in cancer outcomes are prevalent, especially for minority, underserved and rural populations. With a $775,000 one-year grant from the National Cancer Institute (NCI), researchers at Wake Forest Baptist’s Comprehensive Cancer Center are working to reduce those disparities.
UCLA has received seven grants totaling $6.4 million from the California Bureau of Cannabis Control. The awards will fund studies on topics ranging from the toxicity of inhaled and second-hand cannabis smoke to employment conditions in California’s cannabis industry.
• New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection • Research collaboration will lead to valuable insights about pulmonary fibrosis in the growing COVID-19 patient population
A new chemical compound that uses bio-orthogonal click chemistry to target tumor cells while sparing healthy cells has entered clinical trials.
The University of Illinois Chicago will conduct three clinical trials for studying blood clot prevention in patients with COVID-19. The trials are part of the antithrombotics arm of the National Institutes of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines, or ACTIV, initiative.
Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.
Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19
Analysis update by the nonprofit Cancer Research Institute reveals dramatic growth in PD-1/PD-L1 monoclonal antibody combination cancer treatment strategies in global clinical trial pipeline
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right